Corporate Profile

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Minimum 15 minutes delayed. Source: LSEG

News Releases

Events

SEC Filings

Report of unscheduled material events or corporate event

8-K

Report of unscheduled material events or corporate event

8-K

Quarterly report which provides a continuing view of a company's financial position

10-Q